EMA Authorised: Ondibta (insulin glargine) — Sandoz GmbH

View source ↗

Summary

Authorisation of Ondibta (insulin glargine) by Sandoz GmbH for diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Ondibta (insulin glargine)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Sandoz GmbH. Decision date: 12/08/2026